A study of quality assessment in SARS-CoV-2 pathogen nucleic acid amplification tests performance; from the results of external quality assessment survey of clinical laboratories in the Tokyo Metropolitan Government external quality assessment program in


Posted: 2021-11-15 20:00:00
Introduction: The Tokyo Metropolitan Government (TMG) conducted an external quality assessment (EQA) survey of pathogen nucleic acid amplification tests (NAATs) as a TMG EQA program for SARS-CoV-2 for clinical laboratories in Tokyo. Methods: We diluted and prepared a standard product manufactured by Company A to about 2,500 copies/mL to make a positive control and distribute it with a negative control. The participants reported the use of the NAATs methods for SARS-CoV-2, the name of the real-time RT-PCR kit, the name of the detection device, the target gene(s), nucleic acid extraction kit, Threshold Cycle value in the case of RT-PCR and the Threshold time value and Differential calculation value in the case of Loop-Mediated Isothermal Amplification (LAMP) method. Results: As a result, 17 laboratories using fully automated equipment and 34 laboratories using the RT-PCR method reported generally appropriate results in this EQA survey. On the other hand, among the laboratories that adopted the LAMP method, there were a plurality of laboratories that judged positive samples to be negative. Conclusion: The false negative result is considered to be due to the fact that the amount of virus genome contained in the quality control reagent used this time was below the detection limit of the LAMP method combined with the rapid extraction reagent for influenza virus. On the other hand, false positive results are considered to be due to the non-specific reaction of the NAATs. The EQA program must be continued for the proper implementation of the pathogen NAATs. Keywords: COVID-19; External quality control; Loop-mediated isothermal amplification (LAMP) method; Nucleic acid amplification testing; RT-PCR; SARS-CoV-2.

参考サイト PubMed: covid-19


Powered by Vergleichsportal


バイオクイックニュース日本語版:COVID-19特集

バイオクイックニュース日本語版
3月 31, 2021 バイオアソシエイツ

宿主遺伝子の発現を阻害するウイルスタンパク質(Nsp1)を標的としたCOVID-19治療アプローチの可能性

Nsp1と呼ばれるコロナウイルスタンパク質が遺伝子の活性をどのように抑制し、ウイルス複製を促進するかを特定する研究は、新しい COVID-19 治療への希望をもたらすものだ。 パンデミックが始まって以来、科学者らは、 COVID-19 の原因となるコロナウイルスであるSARS-CoV-2を理解するために果てしなく取り組んできた。ワクチンの登場にもかかわらず、ウイルスはまだ蔓延しており、代替療法を開発する必要がある。…

ゲスト 605人 と メンバー 6人 がオンラインです